Shots:
- Roche has launched Elecsys SARS-CoV-2 Ag test as an aid in the diagnosis of SARS-CoV-2 infections, in the markets accepting the CE Mark. Additionally, Roche has also filed a EUA to the US FDA
- The test showed 94.5% sensitivity across 200 PCR confirmed symptomatic individuals & 99.9% specificity across 2747 PCR negative symptomatic & screening individuals in clinical studies. The company plans to ramp up production to have a double-digit million number of tests/ month, in early 2021
- The test is an immunoassay intended for the qualitative detection of SARS-CoV-2 present in the respiratory tract including nasopharynx & oropharynx. The test is the latest addition to Roche’s COVID-19 portfolio
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Business Standard
The post Roche Launches Elecsys SARS-CoV-2 Antigen Test to Support High-Volume COVID-19 Testing first appeared on PharmaShots.
